Uploaded March 2026 | Updated September 2026, 2 weeks ago
New England Journal Article: nejm.org/doi/full/10.1056/NEJMoa2510310
Donate to PCRI: pcri.org/donate
For more information, visit pcri.org
0:42 What does this paper tell us about combining therapies?
4:05 Do second-generation hormone therapies tend to have more side effects?
5:31 Would other second-generation hormone therapies cause less fatigue?
6:35 What makes Xtandi work better in some cases than Lupron alone?
7:47 Are there any comorbidities that might prevent one from going on a second-generation therapy?
8:56 Is a roughly 10% increase in survival all that statistically notable?
10:12 How does treatment duration factor into the decision making process?
12:02 How can patients broach the subject of new treatments with their doctors?
15:23 Alex's conclusions
Don't know your stage? Take the quiz: visit prostatecancerstaging.org
To learn more about prostate cancer, visit pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
New England Journal Article: nejm.org/doi/full/10.1056/NEJMoa2510310
Donate to PCRI: pcri.org/donate
For more information, visit pcri.org
0:42 What does this paper tell us about combining therapies?
4:05 Do second-generation hormone therapies tend to have more side effects?
5:31 Would other second-generation hormone therapies cause less fatigue?
6:35 What makes Xtandi work better in some cases than Lupron alone?
7:47 Are there any comorbidities that might prevent one from going on a second-generation therapy?
8:56 Is a roughly 10% increase in survival all that statistically notable?
10:12 How does treatment duration factor into the decision making process?
12:02 How can patients broach the subject of new treatments with their doctors?
15:23 Alex's conclusions
Don't know your stage? Take the quiz: visit prostatecancerstaging.org
To learn more about prostate cancer, visit pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
